AKT1 and neoplasm: Moreover, it has been reported that a phase 2 study of MK-2206, an Akt inhibitor and selumatinib showed no objective response in patients with colorectal cancer and these inhibitors did not significantly suppress the phosphorylation of ERK1/2 and Akt in tumor tissues [50].